Application and Prospect of Interleukin Receptor Antagonist in the Treatment of Rheumatic Diseases

CHEN Yu-qiang,WANG Nian-song

2012-01-01

Abstract:New biologic agents targeted on the interleukin receptor with less adverse reaction are expected a favorable prospect in the treatment of rheumatic diseases.This review summarizes the efficacy and safety profiles of interleukin receptor antagonist anakinra and tocilizumab.

What problem does this paper attempt to address?

Targeting Fusion Proteins of the Interleukin Family: A Promising New Strategy for the Treatment of Autoinflammatory Diseases.

Yuchen Zhao,Han Wang,Lin Jin,Ziwei Zhang,Lianghu Liu,Mengqi Zhou,Xianzheng Zhang,Lingling Zhang

DOI: https://doi.org/10.1016/j.ejps.2023.106647

IF: 5.112

2024-01-01

European Journal of Pharmaceutical Sciences

Abstract:As a means of communication between immune cells and non-immune cells, Interleukins (ILs) has the main functions of stimulating the proliferation and activation of inflammatory immune cells such as dendritic cells and lymphocytes, promote the development of blood cells and so on. However, dysregulation of ILs expression is a major feature of autoinflammatory diseases. The drugs targeting ILs or IL-like biologics have played an important role in the clinical treatment of autoinflammatory diseases. Nevertheless, the widespread use of IL products may result in significant off-target adverse reactions. Thus, there is a clear need to develop next-generation ILs products in the biomedical field. Fusion proteins are proteins created through the joining of two or more genes that originally coded for separate proteins. Over the last 30 years, there has been increasing interest in the use of fusion protein technology for developing anti-inflammatory drugs. In comparison to single-target drugs, fusion proteins, as multiple targets drugs, have the ability to enhance the cytokine therapeutic index, resulting in improved efficacy over classical drugs. The strategy of preparing ILs or their receptors as fusion proteins is increasingly used in the treatment of autoimmune and chronic inflammation. This review focuses on the efficacy of several fusion protein drugs developed with ILs or their receptors in the treatment of autoinflammatory diseases, in order to illustrate the prospects of this new technology as an anti-inflammatory drug development protocol in the future.
Efficacy and safety of humanized interleukin-6 receptor antibody in treatment of systemic juvenile idiopathic arthritis

Lixia ZOU,Meiping LU,Li GUO,Liping TENG,Yiping XU,Qi ZHENG

DOI: https://doi.org/10.3785/j.issn.1008-9292.2017.08.12

2017-01-01

Abstract:Objective: To evaluate the efficacy and safety of humanized anti-IL-6 receptor monoclonal antibody(tocilizumab)in treatment of systemic juvenile idiopathic arthritis(sJIA).Methods: Thirteen sJIA patients admitted between December 2015 and November 2016 and received tocilizumab treatment were enrolled in the study.The complete blood count(CBC), C-reactive protein(CRP), erythrocyte sedimentation rate(ESR),interleukin-6(IL-6)and ferritin levels were measured;American College of Rheumatology Pediatric(ACR Pedi)30/50/70/90 scores were assessed;and the use of glucocorticosteroid and adverse events were documented.Results: Compared with the baseline levels, the CRP and ESR at d3 were decreased(all P <0.05);hemoglobin was increased and platelet was decreased at week 2(all P<0.05),ferritin decreased at week 4,white blood cell(WBC)decreased at week 8 after treatment with tocilizumab(all P <0.05).The level of IL-6 was rising at d3 and week 2 and descending at week 4, but no significant difference was observed compared with the baseline level(all P>0.05).All 13 patients achieved ACR Pedi 30 remission at week 4,61.5%achieved ACR Pedi 90 remission and glucocorticosteroids were withdrawn at week 20.Twenty two adverse events occurred, and infection accounted for 54.5%(12/22); no severe adverse reactions were observed during 20-week follow-up. Conclusion: Tocilizumab is safe and effective in treatment of sJIA, with decreasing inflammation,improving disease activity and reducing glucocorticosteroid use.
Targeting Interleukin-21 in Rheumatoid Arthritis

Feng-Lai Yuan,Wei Hu,Wei-Guo Lu,Xia Li,Jian-Ping Li,Rui-Sheng Xu,Cheng-Wan Li,Fei-Hu Chen,Cheng Jin

DOI: https://doi.org/10.1007/s11033-010-0285-x

IF: 2.7422

2010-01-01

Molecular Biology Reports

Abstract:Interleukin-21 (IL-21) is a new member of the type I cytokine superfamily, which binds to a composite receptor that consists of a private receptor (IL-21R) and the common cytokine receptor γ chain. Recently, increasing evidence has shown that IL-21 contributes to the pathogenesis of chronic inflammatory and autoimmune diseases because of its pro-inflammatory and immune-mediated properties. IL-21 induced T-cell activation and pro-inflammatory cytokine secretion in rheumatoid arthritis (RA). IL-21R RNA transcripts were found in synovial tissue samples of patients with RA. In addition, blockade of the IL-21/IL-21R pathway ameliorated disease in animal models of RA and significantly inhibited inflammatory cytokine production in vitro. Moreover, IL-21R deficiency in the K/BxN mouse model of inflammatory arthritis was sufficient to block arthritis initiation completely. All theses findings suggest that IL-21 has important biological effects in autoimmunity that might be a promising therapeutic target for RA. In this review, we discuss the biological features of IL-21 and summarize recent advances in the role of IL-21 in the pathogenesis and treatment of RA.
Regulatory Immune Responses Induced by IL-1 Receptor Antagonist in Rheumatoid Arthritis

Xiaoyin Niu,Dongyi He,Shaohua Deng,Weiyi Li,Yebin Xi,Changyi Xie,Ting Jiang,Jingwu Z. Zhang,Chen Dong,Guangjie Chen

DOI: https://doi.org/10.1016/j.molimm.2011.08.020

IF: 4.174

2011-01-01

Molecular Immunology

Abstract:Anakinra, a human recombinant IL-1 receptor antagonist, is approved for the treatment of RA. In this study, 12 patients received the placebo plus MTX treatment, 38 patients received Anakinra combined with MTX treatment. Compared with the placebo plus MTX group, serum levels of IL-17, IFN-γ, IL-21 and IL-1β significantly decreased, the percentages of Th17 cells and Th1 cells were lower and the percentage of Treg cells was higher after receiving Anakinra combined with MTX treatment. The observed regulatory immune responses collectively correlated with clinical improvement in treated patients. A substantial response, ACR 20 at 24 w were consistent with those at 12 w, 16 w and 20 w, and was accompanied by a marked improvement in RA related laboratory parameters. The study reveals that the combination of Anakinra and MTX is safe and well tolerated, which induces regulatory immune responses and significantly provides greater clinical benefit than the placebo plus MTX group.
IL-33: a promising therapeutic target for rheumatoid arthritis?

Feng-Lai Yuan,Xia Li,Wei-Guo Lu,Cheng-Wan Li,Rui-Sheng Xu,Jian Dong

DOI: https://doi.org/10.1517/14728222.2011.560838

IF: 6.797

2011-01-01

Expert Opinion on Therapeutic Targets

Abstract:Cytokine-mediated immunity plays a crucial role in the pathogenesis of various autoimmune diseases, including rheumatoid arthritis (RA). Recently, the IL-1-family-related cytokine, IL-33, was detected at high levels in experimental inflammatory arthritis and in the early phase of human RA, and was reported to exert profound pro-inflammatory effects in several experimental autoimmune models. Moreover, administration of IL-33 leads to the development of severe inflammatory arthritis, suggesting that IL-33 may be therapeutically relevant in RA, and the targeting of IL-33 or the IL-33 receptor has been proposed as a potential therapeutic approach for autoimmune diseases such as RA. In this article, we discuss the biological features of IL-33 and summarize recent advances in our understanding of the role of IL-33 in the pathogenesis and treatment of RA. It is hoped that this information may aid the development of novel therapeutic strategies for RA.</.
The Role of Interleukin-17 in Mediating Joint Destruction in Rheumatoid Arthritis

Xia Li,Feng‐Lai Yuan,Weiguo Lü,Yiqing Zhao,Cheng-wan Li,Jianping Li,Ruirong Xu

DOI: https://doi.org/10.1016/j.bbrc.2010.05.111

IF: 3.1

2010-01-01

Biochemical and Biophysical Research Communications

Abstract:Rheumatoid arthritis (RA) is a chronic, persistent inflammatory joint disease with systemic involvement that affects about 1% of the world's population, that ultimately leads to the progressive destruction of joint. Effective medical treatment for joint destruction in RA is lacking because the knowledge about molecular mechanisms leading to joint destruction are incompletely understood. It has been confirmed that cytokine-mediated immunity plays a crucial role in the pathogenesis of various autoimmune diseases including RA. Recently, IL-17 was identified, which production by Th17 cells. IL-17 has proinflammatory properties and may promote bone and joint damage through induction of matrix metalloproteinases and osteoclasts. In mice, intra-articular injection of IL-17 into the knee joint results in joint inflammation and damage. In addition, it has been shown that blocking IL-17/IL-17R signaling is effective in the control of rheumatoid arthritis symptoms and in the prevention of joint destruction. In this article, we will briefly discuss the biological features of IL-17/IL-17R and summarize recent advances on the role of IL-17/IL-17R in the pathogenesis and treatment of joint destruction in RA.
Interleukin-1 Receptor Antagonist: A New Therapy for Type 2 Diabetes Mellitus

Muhammad Sajid Hamid Akash,Qi Shen,Kanwal Rehman,Shuqing Chen

DOI: https://doi.org/10.1002/jps.23057

IF: 3.8

2012-01-01

Journal of Pharmaceutical Sciences

Abstract:Various complex mechanisms and their multifactorial pathways decisively provoke low-grade local and systemic inflammation in β-cells of pancreatic islets and peripheral tissues to induce β-cells' dysfunction and apoptosis, insulin resistance, and ultimately, overt type 2 diabetes mellitus (T2DM). Conventional antidiabetic agents are being less popular, as they have some potential adverse effects. Currently, many anti-inflammatory therapeutic modalities are being investigated to abate the infuriating effects of inducers of T2DM and among them, interleukin-1 receptor antagonist (IL-1Ra) is the only one that has been approved by US Food and Drug Administration. We have compared IL-1Ra with other anti-inflammatory agents and conventional antidiabetic agents. Although, IL-1Ra has broad-spectrum anti-inflammatory activities, it also has some limitations due to its short half-life. To overcome the problem of short half-life of IL-1Ra, recently, we fused IL-1Ra in recombinant human serum albumin and expressed it in Pichia pastoris. Its bioactivity was also checked by IL-1-induced A375.S2 apoptotic cells. Furthermore, we have also formulated IL-1Ra with Pluronic F-127-based thermosensitive gel and investigated its in vitro characteristics to prolong its therapeutic effects. Further studies are required to investigate its therapeutic effects against diabetes and diabetes-associated complications. © 2012 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 101:1647–1658, 2012
[Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-interleukins]

Seung Min Hong,Won Moon

DOI: https://doi.org/10.4166/kjg.2024.076

2024-08-25

Abstract:Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic inflammatory disease of the gastrointestinal tract. The introduction of biologics, particularly anti-interleukin (IL) agents, has revolutionized IBD treatment. This review summarizes the role of ILs in IBD pathophysiology and describes the efficacy and positioning of anti-IL therapies. We discuss the functions of key ILs in IBD and their potential as therapeutic targets. The review then discusses anti-IL therapies, focusing primarily on ustekinumab (anti-IL-12/23), risankizumab (anti-IL-23), and mirikizumab (anti-IL-23). Clinical trial data demonstrate their efficacy in inducing and maintaining remission in Crohn's disease and ulcerative colitis. The safety profiles of these agents are generally favorable. However, long-term safety data for newer agents are still limited. The review also briefly discusses emerging therapies such as guselkumab and brazikumab. Network meta-analyses suggest that anti-IL therapies perform well compared to other biological agents. These agents may be considered first- or second-line therapies for many patients, especially those with comorbidities or safety concerns. Anti-IL therapies represent a significant advancement in IBD treatment, offering effective and relatively safe options for patients with moderate to severe disease.
Adverse reactions to interleukin-17A and its receptor antagonists in the treatment of psoriasis

王若珺,李若瑜

DOI: https://doi.org/10.35541/cjd.20190858

2021-01-01

Chinese Journal of Dermatology

Abstract:Interleukin (IL) -17A plays a key role in the occurrence and development of psoriasis. To date, several marketed IL-17A and its receptor antagonists have been applied to the treatment of psoriasis, and definite therapeutic effects have been achieved. However, several adverse reactions, including upper respiratory tract infection, Candida infections, neutropenia, inflammatory bowel disease, which can be life-threatening, have been reported in clinical trials and after marketing of these biologics. This review summarizes clinical safety profiles of 3 types of interleukin-17A and its receptor antagonists, i.e., secukinumab, ixekizumab and brodalumab.
Therapeutic potential of interleukin-17 in inflammation and autoimmune diseases.

Jun-Wei Yan,Yu-Jie Wang,Wen-Jia Peng,Jin-Hui Tao,Ya-Nan Wan,Bao-Zhu Li,Bin Mei,Bing Chen,Hua Yao,Guo-Jun Yang,Xiang-Pei Li,Dong-Qing Ye,Jing Wang

DOI: https://doi.org/10.1517/14728222.2013.843669

IF: 6.797

2013-01-01

Expert Opinion on Therapeutic Targets

Abstract:INTRODUCTION:Interleukin-17 (IL-17) is a proinflammatory cytokine that mainly produced by T helper 17 (Th17) cells. In this article, we discussed the role of IL-17 in inflammation and autoimmune diseases, and the therapeutic strategies targeting IL-17. AREAS COVERED:In this article, we discussed the proinflammatory cytokine IL-17 and IL-17 receptors signals, and their regulation. IL-17 expression was abnormal in the bacterium, virus and fungus infection, and its higher level caused the tissue inflammation. IL-17 was involved in the pathological process of autoimmune diseases, such as systemic sclerosis, rheumatoid arthritis, ankylosing spondylitis and systemic lupus erythematosus, and IL-17 has been put as a therapeutic target in the clinic. EXPERT OPINION:IL-17/IL-17R signals and their application in inflammation process still need to be explored. Therapeutic strategies targeting IL-17 in autoimmune diseases ameliorated the inadequate response to anti-TNF-α therapy.
Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis

Jun Bao,Tao Yue,Wei Liu,Qing Zhang,Ling Zhou,Hu-Ji Xu,Sheng-Ming Dai

DOI: https://doi.org/10.1007/s10067-010-1654-5

2011-01-01

Clinical Rheumatology

Abstract:The aim of this study is to assess the efficacy of anakinra, a recombinant human interleukin 1 receptor antagonist, plus methotrexate (MTX) in patients with active rheumatoid arthritis (RA) refractory to MTX therapy. A total of 54 patients with active RA, who were taking MTX at a stable dosage, were randomized to receive daily subcutaneous injections of anakinra (80 mg) or placebo. Clinical outcomes were assessed every 4 weeks for 24 weeks by using the criteria of the American College of Rheumatology. After 24 weeks, more patients achieved clinical benefits as determined by the ACR20 improvement treated with anakinra plus MTX compared with MTX alone (64% vs. 17%, P = 0.004). In the anakinra group, an ACR50 response was observed in 38% and an ACR70 response in 17%. None of the patients treated with MTX alone achieved ACR50 or ACR 70 improvement. However, nine of 42 (21.4%) patients in the anakinra group, who showed therapeutic response initially, had secondary drug failure to anakinra therapy thereafter. A significant increase in mean DAS28 from baseline was found in the non-responders to anakinra compared with placebo (0.83 ± 1.38 vs. −1.28 ± 0.78, P < 0.001). Anakinra is effective in the treatment of patients with active RA by blocking IL-1. However, the efficacy of anakinra is soon lost in about one fifth of patients in spite of initial good response.
The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis

Yoshiyuki Ohsugi,Tadamitsu Kishimoto

DOI: https://doi.org/10.1517/14712598.8.5.669

2008-04-13

Expert Opinion on Biological Therapy

Abstract:BACKGROUND: IL-6 is a pro-inflammatory cytokine with multiple roles in the pathogenesis of rheumatoid arthritis (RA). Targeting IL-6 with the humanized anti IL-6 receptor antibody tocilizumab was effective in several placebo-controlled clinical studies in RA.OBJECTIVES: To address how clinically efficacious blockade of IL-6 signalling with inteleukin-6 receptor antibody is in RA patients and what the potential mode of action explaining tocilizumab activity in RA treatment could be.RESULTS/CONCLUSION: IL-6 induces autoantibody-producing plasma cells and effector T cells and is implicated in the development of clinical signs and symptoms, including increased synthesis of acute phase reactants, fatigue, anaemia and anorexia. Its effects also included significant improvements in American College of Rheumatology (ACR)20, ACR50 and ACR70 values, as well as in health-related quality of life measures, compared with controls. Tocilizumab also prevents radiographic progression of joint damage. Tocilizumab is generally well tolerated and efficacious in patients refractive to conventional DMARD therapies.

medicine, research & experimental,biotechnology & applied microbiology
[IL-6: the next key target for rheumatoid arthritis after TNF-α].

Weiting Zhang,Yanyi Li

DOI: https://doi.org/10.13345/j.cjb.160241

2017-01-25

Abstract:IL-6 is an important cytokine that plays an important role in the pathogenesis of rheumatoid arthritis. We summarized the clinical efficacy and safety of tocilizumab, the IL-6 receptor monoclonal antibody in rheumatoid arthritis, and compared tocilizumab with TNF-α blocking mAbs. The efficiency of tocilizuamb is equivalent to that of TNF-α blockers, and each of the drugs has its advantages and disadvantages. We also summarized the clinical trials of the mAbs blocking IL-6 pathway in development. According to the results of recent studies by several research teams including our research group, IL-6 is another key target for the treatment of rheumatoid arthritis after TNF-α. The listing of the IL-6 blockers provides more choices for personalized treatment of rheumatoid arthritis in the future.

Medicine
The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases

Yi-Ru Bai,Wei-Guang Yang,Xue-Hui Hou,Dan-Dan Shen,Sheng-Nan Zhang,Yan Li,Yan-Yan Qiao,Sai-Qi Wang,Shuo Yuan,Hong-Min Liu

DOI: https://doi.org/10.1016/j.ejmech.2023.115606

IF: 7.088

2023-06-29

European Journal of Medicinal Chemistry

Abstract:The interleukin-1 receptor associated kinase 4 (IRAK-4) is a member of serine-threonine kinase family, which plays an important role in the regulation of interleukin-1 receptors (IL-1R) and Toll-like receptors (TLRs) related signaling pathways. At present, the IRAK-4 mediated inflammation and related signaling pathways contribute to inflammation, which are also responsible for other autoimmune diseases and drug resistance in cancers. Therefore, targeting IRAK-4 to develop single-target, multi-target inhibitors and proteolysis-targeting chimera (PROTAC) degraders is an important direction for the treatment of inflammation and related diseases. Moreover, insight into the mechanism of action and structural optimization of the reported IRAK-4 inhibitors will provide the new direction to enrich the clinical therapies for inflammation and related diseases. In this comprehensive review, we introduced the recent advance of IRAK-4 inhibitors and degraders with regards to structural optimization, mechanism of action and clinical application that would be helpful for the development of more potent chemical entities against IRAK-4.

chemistry, medicinal
IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONS

E. L. Nasonov,T. V. Korotaeva,T. V. Dubinina,A. M. Lila

DOI: https://doi.org/10.14412/1995-4484-2019-400-406

2019-09-16

Rheumatology Science and Practice

Abstract:Recently, more attention has been given to Th17 cells, the pathological activation of which plays a leading role in the development of a wide spectrum of human immunoinflammatory diseases (IID), including rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis, inflammatory bowel diseases, etc. This has served as an incentive to design new biological agents and small molecules, the main mechanism of action of which is based on blocking the pathological effects of interleukin-17 (IL-17), others are associated with the activation of Th17 cells cytokines or signaling pathways that regulate the effects of these cytokines. The review discusses current ideas about the mechanisms regulating the formation and functional activity of IL-17 family cytokines, as well as evidence for the importance of these cytokines in the pathogenesis of IID.
Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases

Carlos Rafael-Vidal,Nair Pérez,Irene Altabás,Samuel Garcia,Jose M. Pego-Reigosa

DOI: https://doi.org/10.3390/ijms21197100

IF: 5.6

2020-09-26

International Journal of Molecular Sciences

Abstract:Systemic rheumatic diseases are a heterogeneous group of autoimmune disorders that affect the connective tissue, characterized by the involvement of multiple organs, leading to disability, organ failure and premature mortality. Despite the advances in recent years, the therapeutic options for these diseases are still limited and some patients do not respond to the current treatments. Interleukin-17 (IL-17) is a cytokine essential in the defense against extracellular bacteria and fungi. Disruption of IL-17 homeostasis has been associated with the development and progression of rheumatic diseases, and the approval of different biological therapies targeting IL-17 for the treatment of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) has highlighted the key role of this cytokine. IL-17 has been also implicated in the pathogenesis of systemic rheumatic diseases, including systemic lupus erythematosus (SLE), Sjögren’s syndrome (SS) and systemic sclerosis (SSc). The aim of this review is to summarize and discuss the most recent findings about the pathogenic role of IL-17 in systemic rheumatic and its potential use as a therapeutic option.
Rheumatoid arthritis: non-tumor necrosis factor targets

Louise Pollard,Ernest Choy

DOI: https://doi.org/10.1097/01.bor.0000159927.19891.eb

2005-05-01

Current Opinion in Rheumatology

Abstract:PURPOSE OF REVIEW: The treatment of rheumatoid arthritis has been revolutionised in recent years with the advent of biologic treatments. The purpose of this review is to outline new treatments that target the inflammatory pathway in rheumatoid arthritis other than tumor necrosis factor-alpha.RECENT FINDINGS: As the use of anti-tumor necrosis factor-alpha treatment has become more widespread, the number of patients in whom this treatment is unsuccessful has also accumulated. Contraindications such as infection and cardiac failure further add to the number of patients who need alternative treatment. A better understanding of the inflammatory pathway in rheumatoid arthritis has led to interest in other therapeutic targets. Promising treatments such as interleukin-6 antagonists (MRA), CTLA4Ig (abatacept), and anti-B cell therapy (rituximab) have already been tested in randomized controlled trials over the past year. Other cytokines have been identified and have been shown to be of benefit in animal models, including interleukin-15, interleukin-17, and interleukin-18, and clinical trials of these agents are currently under way.SUMMARY: For patients with rheumatoid arthritis that does not respond to anti-tumor necrosis factor-alpha treatment, the promising alternatives MRA, abatacept, and rituximab have been tested. It is hoped that these agents will become available shortly.

rheumatology
A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential

Xiaolei Liu,Li Li,Qian Wang,Fengchao Jiang,Pei Zhang,Fei Guo,Hongjun Liu,Jian Huang

DOI: https://doi.org/10.3389/fimmu.2021.816646

IF: 7.3

2022-01-19

Frontiers in Immunology

Abstract:Interleukin-6 (IL-6), a pleiotropic cytokine that regulates immune responses and inflammatory reactions, plays a pivotal role in the development of rheumatoid arthritis (RA). Blockade of IL-6 signaling with the monoclonal antibody (mAb) represents an important advancement in RA treatment. Although two IL-6 receptor antibodies are already available in the clinic, there is no mAb specifically targeting the human IL-6 to block IL-6 signaling for RA treatment. In this study, we have developed a novel humanized anti-IL-6 mAb HZ-0408b with potent binding and neutralizing activity to human IL-6. We demonstrated that HZ-0408b has a high species specificity and low cross-reactivity. Moreover, HZ-0408b showed a more potent inhibitory effect on IL-6 signaling than Siltuximab, an FDA-approved anti-IL-6 chimeric mAb. HZ-0408b is comparable to Olokizumab, a humanized mAb against IL-6 that is already in phase III studies. We observed that HZ-0408b is well tolerated at doses that can achieve therapeutic serum levels in cynomolgus monkey. Most importantly, we proved that HZ-0408b treatment significantly ameliorated joint swelling after the onset of arthritis and dramatically reduced plasma C-reactive protein (CRP) levels in a monkey collagen-induced arthritis (CIA) model. Collectively, our findings using non-human primates indicate that humanized anti-IL-6 mAb HZ-0408b has excellent safety and efficacy profiles for RA therapy.

immunology
Anakinra Therapy for Non-cancer Inflammatory Diseases

Giulio Cavalli,Charles A. Dinarello

DOI: https://doi.org/10.3389/fphar.2018.01157

IF: 5.6

2018-11-06

Frontiers in Pharmacology

Abstract:Interleukin-1 (IL-1) is the prototypical inflammatory cytokine: two distinct ligands (IL-1α and IL-1β) bind the IL-1 type 1 receptor (IL-1R1) and induce a myriad of secondary inflammatory mediators, including prostaglandins, cytokines, and chemokines. IL-1α is constitutively present in endothelial and epithelial cells, whereas IL-1β is inducible in myeloid cells and released following cleavage by caspase-1. Over the past 30 years, IL-1-mediated inflammation has been established in a broad spectrum of diseases, ranging from rare autoinflammatory diseases to common conditions such as gout and rheumatoid arthritis (RA), type 2 diabetes, atherosclerosis, and acute myocardial infarction. Blocking IL-1 entered the clinical arena with anakinra, the recombinant form of the naturally occurring IL-1 receptor antagonist (IL-1Ra); IL-1Ra prevents the binding of IL-1α as well as IL-1β to IL-1R1. Quenching IL-1-mediated inflammation prevents the detrimental consequences of tissue damage and organ dysfunction. Although anakinra is presently approved for the treatment of RA and cryopyrin-associated periodic syndromes, off-label use of anakinra far exceeds its approved indications. Dosing of 100 mg of anakinra subcutaneously provides clinically evident benefits within days and for some diseases, anakinra has been used daily for over 12 years. Compared to other biologics, anakinra has an unparalleled record of safety: opportunistic infections, particularly Mycobacterium tuberculosis, are rare even in populations at risk for reactivation of latent infections. Because of this excellent safety profile and relative short duration of action, anakinra can also be used as a diagnostic tool for undefined diseases mediated by IL-1. Although anakinra is presently in clinical trials to treat cancer, this review focuses on anakinra treatment of acute as well as chronic inflammatory diseases.

pharmacology & pharmacy
Anti-inflammatory Effects of Interleukin-23 Receptor Cytokine-Binding Homology Region Rebalance T Cell Distribution in Rodent Collagen-Induced Arthritis

Wei Guo,Dongmei Yu,Xin Wang,Cheng Luo,Yucong Chen,Wen Lei,Chen Wang,Yaoyao Ge,Wenyao Xue,Qiqi Tian,Xiangdong Gao,Wenbing Yao

DOI: https://doi.org/10.18632/oncotarget.9309

2016-01-01

Oncotarget

Abstract:IL-23 is an important cytokine to regulate Th17 cell differentiation and promote the proliferation of inflammatory cells inTh17-mediated autoimmune diseases.The collagen-induced arthritis (CIA) in rat is a model of rheumatoid arthritis characterized by pronounced inflammatory auto-responses from B and T cells, especially Th17 cells in lesions.In the present study, we used rhIL23R-CHR to block the IL-23 signaling pathway to probe the importance of IL-23 in misbalancing the ratio of Th17/Th9/Treg cells in CIA rats.After treatments with rhIL23R-CHR, the CIA rats showed a significant decrease of secretions of IL-17 and IL-9, whereas FoxP3 was activated in the process, indicating that IL-23 can manipulate the balance of Th17/Th9/Treg cells.Similar to the animal model, IL-23 also possessed remarkable proinflammatory effects on human fibroblast-like synoviocyte cells (HFLS), showing synergetic outcomes with TNF-α.Together, IL-23 could act as a modulator to imbalance the ratio of Th17/Th9/Treg cells, and rhIL23R-CHR could serve as a potential therapeutic agent for RA patients.

Application and Prospect of Interleukin Receptor Antagonist in the Treatment of Rheumatic Diseases

Targeting Fusion Proteins of the Interleukin Family: A Promising New Strategy for the Treatment of Autoinflammatory Diseases.

Efficacy and safety of humanized interleukin-6 receptor antibody in treatment of systemic juvenile idiopathic arthritis

Targeting Interleukin-21 in Rheumatoid Arthritis

Regulatory Immune Responses Induced by IL-1 Receptor Antagonist in Rheumatoid Arthritis

IL-33: a promising therapeutic target for rheumatoid arthritis?

The Role of Interleukin-17 in Mediating Joint Destruction in Rheumatoid Arthritis

Interleukin-1 Receptor Antagonist: A New Therapy for Type 2 Diabetes Mellitus

[Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-interleukins]

Adverse reactions to interleukin-17A and its receptor antagonists in the treatment of psoriasis

Therapeutic potential of interleukin-17 in inflammation and autoimmune diseases.

Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis

The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis

[IL-6: the next key target for rheumatoid arthritis after TNF-α].

The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases

IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONS

Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases

Rheumatoid arthritis: non-tumor necrosis factor targets

A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential

Anakinra Therapy for Non-cancer Inflammatory Diseases

Anti-inflammatory Effects of Interleukin-23 Receptor Cytokine-Binding Homology Region Rebalance T Cell Distribution in Rodent Collagen-Induced Arthritis